2022 Breast Cancer Summer Forum·Northern Salon｜Professor Wang Xiaojia explains the application of CDK4/6 inhibitors in breast cancer patients

"2022 Breast Cancer Summer Forum·Northern Salon" will be held in Beijing on July 30, 2022

Professor Wang Xiaojia

Cancer Hospital Affiliated to University of Chinese Academy of Sciences (Zhejiang Cancer Hospital)

• Member of the Party Committee and Assistant to the President of University Cancer Hospital, Chinese Academy of Sciences

• Director of the Department of Science and Education, Director of Breast Internal Medicine, Doctoral/Doctoral Supervisor, Chief Physician

• Deputy Director of Zhejiang Provincial Cancer Intelligence Diagnosis and Molecular Technology Major Disease Diagnosis and Treatment Technology Research Center

• Member of the National Health Commission's Rational Drug Use Expert Group and Director of the Breast Cancer Practice Base

• Member of the Breast Cancer Special Committee of the National Cancer Center for Quality Control

• Deputy Director of Zhejiang Cancer Diagnosis and Treatment Quality Control Center and Chairman of Breast Cancer Expert Committee

• Deputy Chairman of CSCO Breast Cancer Expert Committee

• Member of the Standing Committee of Breast Cancer Professional Committee of China Anti-Cancer Association

• Chairman of the Medical Oncology Professional Committee of Zhejiang Anti-Cancer Association, and Chairman-designate of the Breast Cancer Professional Committee

• Vice Chairman of Zhejiang Provincial Society of Immunology

• Vice President of Zhejiang Translational Medicine Society and President of Precision Medicine Branch

Yimaitong: A few days ago, you as the corresponding author "Research Progress on the Mechanism of CDK4/6 Inhibitors to Promote Anti-tumor Immunity by Regulating the Immune Microenvironment of Triple-Negative Breast Cancer" was published in "International Journal of Oncology", please give us a brief introduction What are the advantages of CDK4/6 inhibitor combined immunotherapy?

Yimaitong: In recent years, CDK4/6 inhibitors have developed rapidly.

The application of CDK4/6 inhibitors has improved this situation to a large extent.

Yimaitong: For patients with metastatic breast cancer who have failed CDK4/6 inhibitor therapy, can you please talk about the current clinical options for follow-up treatment for such patients?

However, the efficacy of these regimens is significantly different from that of first- and second-line CDK4/6 inhibitors.

With this as a starting point, the researchers conducted a large number of drug resistance analyses in patients who had progressed on CDK4/6 inhibitor therapy
.

The results show that the mutation of signaling pathways in such patients is relatively common.
Therefore, in the follow-up of targeted therapy or targeted combined endocrine therapy for such patients, it is necessary to carry out precise treatment of patients through disease classification standards that are closer to the clinic
.

At present, HDAC inhibitors, PI3K inhibitors, ADC and other drugs have been exploratively used in the follow-up treatment of such patients, but there is still a lot of room for improvement in clinical benefits
.

Based on the above information, at present, there is a bottleneck in the clinical application of follow-up treatment for patients after CDK4/6 inhibitor treatment fails.
Explore
.

Edit: Youshi

Reviewer: Professor Wang Xiaojia

Typography: Youshi

Execution: Traveller